A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition (scientific article published on 17 January 2013)

A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib

Q33597519

Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.

Q33806087

A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy

Q33833506

An alternative splicing network links cell-cycle control to apoptosis

Q34077168

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

Q34157874

Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2.

Q34206916

Preferential induction of apoptosis for primary human leukemic stem cells

Q34415832

Gene expression changes associated with progression and response in chronic myeloid leukemia

Q34479561

Blastic phase of chronic myelogenous leukemia

Q34514042

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

Q35075545

Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy.

Q35640320

Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias

Q35811198

Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications.

Q35874924

The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry

Q35917268

Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome

Q36250937

Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo

Q36488720

BCL2 family in DNA damage and cell cycle control

Q36501194

Bcl-2-family proteins and hematologic malignancies: history and future prospects

Q36508817

Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia

Q36685759

Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors

Q36686170

Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy

Q37060530

Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation

Q37106907

Resistance and relapse with imatinib in CML: causes and consequences.

Q37132439

Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance

Q37178380

Bcl-2 inhibitors: small molecules with a big impact on cancer therapy

Q37275477

Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML.

Q37379434

Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease

Q37511071

Cancer stem cells in solid tumors.

Q37725326

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.

Q38332509

Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL.

Q38338829

Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins

Q39833330

Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer.

Q40134202

Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

Q40252270

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

Q40549569

BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells

Q40630003

Bcr/Abl activates transcription of the Bcl-X gene through STAT5.

Q40856047

BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.

Q40886681

Exon skipping in Mcl-1 results in a bcl-2 homology domain 3 only gene product that promotes cell death

Q40886763

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

Q41356541

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

Q41743756

MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family

Q41839159

The CML stem cell: evolution of the progenitor

Q42135962

Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL

Q42139163

Hematopoietic stem cells and other hematopoietic cells show broad resistance to chemotherapeutic agents in vivo when overexpressing bcl-2.

Q42168728

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

Q43977683

The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells

Q44078274

Involvement of the B-lymphoid system in chronic myelogenous leukaemia

Q44356609

Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation

Q44926251

Discontinuation of imatinib therapy after achieving a molecular response

Q45065538

Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia

Q46247309

(-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells

Q46958467

Stem cell gene expression programs influence clinical outcome in human leukemia.

Q51856192

A distinctive DNA damage response in human hematopoietic stem cells reveals an apoptosis-independent role for p53 in self-renewal.

Q51904571

Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival

Q59607019

Expression of a bcl-2 transgene reduces proliferation and slows turnover of developing B lymphocytes in vivo

Q62817870

bcl-2 transgene expression promotes survival and reduces proliferation of CD3-CD4-CD8- T cell progenitors

Q62817888

Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia

Q64008436

Enhanced detection, maintenance, and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human steel factor, interleukin-3, and granulocyte colony-stimulating factor

Q71775685

Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice

Q79235569

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

leukemia

Q29496

P304

page(s)

316-328

P577

publication date

2013-01-17

P1433

published in

Cell Stem Cell

Q2943975

P1476

title

A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition

P478

volume

Reverse relations

cites work (P2860)

Q49951210	A matter of life and death: stem cell survival in tissue regeneration and tumour formation
Q41355445	A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia
Q39689950	ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis.
Q28084243	Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells
Q35931271	Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond
Q46027484	Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma.
Q35124728	An RNA editing fingerprint of cancer stem cell reprogramming
Q34117463	Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival
Q37273208	BCL-2 inhibition impairs mitochondrial function and targets oral tongue squamous cell carcinoma
Q42098578	BCL-2 inhibition: stemming the tide of myeloid malignancies
Q38694287	BCR-ABL1-positive microvesicles malignantly transform human bone marrow mesenchymal stem cells in vitro
Q58763373	BH3 mimetics induce apoptosis independent of DRP-1 in melanoma
Q39038331	BH3 mimetics suppress CXCL12 expression in human malignant peripheral nerve sheath tumor cells
Q38998882	CD99 is a therapeutic target on disease stem cells in myeloid malignancies
Q38268164	Cancer stem cells: are they responsible for treatment failure?
Q35679898	Capillary Isoelectric Focusing Immunoassay for Fat Cell Differentiation Proteomics.
Q28396457	Capillary nano-immunoassays: advancing quantitative proteomics analysis, biomarker assessment, and molecular diagnostics
Q38866390	Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.
Q64114070	Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities
Q92282773	Chronic myeloid leukemia stem cells
Q37416797	Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
Q26995268	Concise review: Leukemia stem cells in personalized medicine
Q92254021	Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models
Q90647565	Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia
Q99248489	Declaration of Bcr-Abl1 independence
Q38322466	Delivery of therapeutics using nanocarriers for targeting cancer cells and cancer stem cells
Q47670493	Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia.
Q41490128	Drug target optimization in chronic myeloid leukemia using innovative computational platform
Q39109931	EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression
Q34486401	Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer
Q42330444	Eradication of CML stem cells
Q41964206	Evaluation and critical assessment of putative MCL-1 inhibitors.
Q46370948	Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax
Q40079691	GLI2 inhibition abrogates human leukemia stem cell dormancy
Q38177162	Genetic events other than BCR-ABL1.
Q90429716	Gossypol Inhibits Non-small Cell Lung Cancer Cells Proliferation by Targeting EGFRL858R/T790M
Q26801037	Harnessing the apoptotic programs in cancer stem-like cells
Q38845834	How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety
Q28540799	Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias
Q35859229	Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia
Q38957684	Inhibition of NANOG/NANOGP8 downregulates MCL-1 in colorectal cancer cells and enhances the therapeutic efficacy of BH3 mimetics
Q38846360	Intersection of mitochondrial fission and fusion machinery with apoptotic pathways: Role of Mcl-1.
Q38175466	Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia
Q38118817	Leukemia stem cells: Old concepts and new perspectives
Q36140893	Mcl-1 is an important therapeutic target for oral squamous cell carcinomas
Q38622874	Mechanisms of tumour resistance against chemotherapeutic agents in veterinary oncology
Q38602633	Minimal Residual Disease Eradication in CML: Does It Really Matter?
Q38164593	Modeling normal and malignant human hematopoiesis in vivo through newborn NSG xenotransplantation
Q30457748	Nanoimmunoassay to Detect Responses in Head and Neck Cancer: Feasibility in a Mouse Model
Q49887884	Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
Q35579430	Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing
Q52846906	Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer.
Q34444620	Novel targeted therapies for eosinophil-associated diseases and allergy
Q39406329	Overview of Cancer Stem Cells and Stemness for Community Oncologists
Q42938836	PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche
Q89595398	Post-Transcriptional Regulation of Homeostatic, Stressed, and Malignant Stem Cells
Q48316021	Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling
Q91863573	Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells
Q35635358	Quiescent sox2(+) cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma
Q42734570	RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AML
Q39247132	RNA editing-dependent epitranscriptome diversity in cancer stem cells
Q37576728	Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons
Q38206835	Reactive oxygen species regulate hematopoietic stem cell self-renewal, migration and development, as well as their bone marrow microenvironment
Q38128358	Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer
Q42499317	Restrained Terminal Differentiation and Sustained Stemness in Neonatal Skin by Ha-Ras and Bcl-2.
Q36394240	Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal
Q42111132	Sensitizing acute myeloid leukemia cells to induced differentiation by inhibiting the RIP1/RIP3 pathway
Q52900925	Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer.
Q92242813	Stem Cell Plasticity and Dormancy in the Development of Cancer Therapy Resistance
Q36544358	Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells
Q24596026	Systematic review of dasatinib in chronic myeloid leukemia
Q89947291	Targeting BCL-2 as a Therapeutic Strategy for Primary p210BCR-ABL1-positive B-ALL Cells
Q26853686	Targeting BCL2-Proteins for the Treatment of Solid Tumours
Q57461994	Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia
Q38149736	Targeting cancer stem cells to suppress acquired chemotherapy resistance
Q37395704	Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia
Q33418324	The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors
Q38645695	The Implications and Future Perspectives of Nanomedicine for Cancer Stem Cell Targeted Therapies.
Q92453398	The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
Q48121335	The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells.
Q41896472	The secret life of quiescent cancer stem cells
Q51818965	Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies.
Q27324269	Tracking of Normal and Malignant Progenitor Cell Cycle Transit in a Defined Niche.
Q94673038	Transcriptome profiling reveals the high incidence of hnRNPA1 exon 8 inclusion in chronic myeloid leukemia
Q87842370	We skip to work: alternative splicing in normal and malignant myelopoiesis